JIM CRAMERAbbVie, Nokia, Lululemon Athletica: 'Mad Money' Lightning RoundBy Scott RuttNov 21, 2019 8:39 PM EST
STOCKS15 Biotech Firms That Have Strong Potential to Be Acquired: JefferiesBy Kinsey GrantMar 20, 2018 2:58 PM EDT
JIM CRAMERDelta Air Lines, BioTelemetry, TransUnion: 'Mad Money' Lightning RoundBy Scott RuttOct 17, 2017 9:27 PM EDT
JIM CRAMERAre Stocks Cheaper Than We Think?: Cramer's 'Mad Money' RecapBy Scott RuttOct 17, 2017 9:14 PM EDT
HEALTHCelgene, Vertex and Spark Among Jefferies' Top Biotech PicksBy Armie Margaret LeeJul 14, 2017 4:11 PM EDT
HEALTHBiotech Movers: Akebia Shares Down After Pricing Stock OfferingBy Armie Margaret LeeJun 29, 2017 9:26 AM EDT
STOCKSApple Could Explode Higher to $200 a Share If This Chart Pattern Is CorrectBy Roberto PedoneJun 9, 2017 1:19 PM EDT
JIM CRAMERAlibaba, Coherent, Advanced Micro Devices: 'Mad Money' Lightning RoundBy Scott RuttApr 11, 2017 6:20 AM EDT
JIM CRAMERThese Sleeper Stocks Are Soaring: Cramer's 'Mad Money' RecapBy Scott RuttApr 11, 2017 6:11 AM EDT
HEALTHBiotech Premarket Movers: Esperion, Minerva and BioCrystBy Armie Margaret LeeMar 21, 2017 9:32 AM EDT
STOCKSHow to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and MoreBy Jonas ElmerrajiMar 20, 2017 2:03 PM EDT
JIM CRAMERPaylPal, CH Robinson Worldwide, Texas Instruments: 'Mad Money' Lightning RoundBy Scott RuttFeb 28, 2017 6:20 AM EST
JIM CRAMERHere's Why Buffett Is So Bullish About This Market: Cramer's 'Mad Money' RecapBy Scott RuttFeb 28, 2017 6:15 AM EST
STOCKSPremarket biotech movers: Portola, Esperion, MedicinesBy Armie Margaret LeeFeb 3, 2017 9:32 AM EST
STOCKSEsperion Falls on Regulatory Setback for Cholesterol-Lowering PillBy Adam FeuersteinJun 28, 2016 4:43 PM EDT
JIM CRAMER'Mad Money' Lightning Round: Forget Revance, I Want AllerganBy Scott RuttNov 13, 2015 6:00 AM EST
JIM CRAMERJim Cramer's 'Mad Money' Recap: There's Negative, and There's Too NegativeBy Scott RuttNov 12, 2015 8:42 PM EST
MARKETSWhy Esperion Therapeutics (ESPR) Stock is Climbing TodayBy Tony OwusuOct 12, 2015 10:11 AM EDT
STOCKSLilly Sinks as Cholesterol-Lowering Pill Trial Shut DownBy Adam FeuersteinOct 12, 2015 9:46 AM EDT
STOCKSAmicus, Other Biotech CEOs Should Listen More, Talk Less About FDA MattersBy Adam FeuersteinOct 2, 2015 10:43 AM EDT
